tirzepatide cardiovascular risk linked to lower for death, adverse CV and kidney outcomes vs. GLP-1s Effect of tirzepatide (TZP) on

If youre considering or already taking a GLP-1 agonist, its best to discuss your individual situation with your oncologist or primary care team, especially if you have other risk factors

This is where concentration becomes critical

People usually get the safest and most effective care by working closely with their primary care provider or a board-certified obesity medicine physician [if they can no longer afford the medication]

One study shows that each year, 0.25% of people with atrophic gastritis develop stomach cancer, and 0.68% develop a certain type of cancerous tumor in their stomach

However, more extensive clinical trials are necessary to establish long-term effects on glycemic control and complications